The discovery of new DHODH inhibitors, as well as a novel strategy to increase p53 activation and synergism with mdm2 inhibitors offers an exciting prospect to bring p53 therapy to fruition and may allow the cure of diseases like CML that retain resistance to elimination via a p53 sensitive stem cell population2. The gene discussed is TP53; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.